探讨核苷酸还原酶亚单位M1( RRM1)和核苷酸切除修复交叉互补基因1(ERCC1)蛋白在ⅢB和Ⅳ期非小细胞肺癌(NSCLC)中的表达,及其与吉西他滨联合顺铂(GP)方案化疗疗效的关系.方法 采用免疫组化SP法检测135例ⅢB和Ⅳ期、经过4周期以上GP方案化疗的NSCLC组织RRM1和ERCC1的表达情况.结果 RRM1和ERCC1蛋白表达情况与性别、年龄、组织病理学类型、吸烟史、临床分期和ECOG评分均无关(P＞0.05).RRM1与ERCC1蛋白表达显著正相关(r=0.586,P＜0.001).RRM1和ERCC1表达均为阴性组的有效率为71.4％,疾病进展时间为(10.59±4.47)个月,中位生存时间为14.55个月；两者表达均为阳性组分别为20.0％、(7.50±4.57)个月和10.32个月；两者表达任一阳性组分别为58.1％、(9.40±4.08)个月和12.87个月,3组之间比较差异均有统计学意义(P＜0.05).结论 肺癌组织RRM1和ERCC1蛋白表达情况能够预测晚期NSCLC应用GP方案化疗的疗效.%Objective To investigate the relationship between the expression of RRM1 and ERCC1 and the efficacy of chemotherapy in stage ⅢB/Ⅳ non-small cell lung cancer( NSCLC) patients treated by gemcitabine/cisplatin chemotherapy ( GP regimen). Methods One hundred and thirty-five cases of stage ⅢB/Ⅳ NSCLC patients were included. Bronchoscopy tumor biopsies or lung puncture tumor biopsies were detected by immunohistochemical staining. The patients were treated by at least 4 cycles of GP regimen. The relationship between the expression of RRM1 and ERCC1 and chemotherapeutic effect was analyzed. Results The expression of RRM1 and ERCC1 had no correlation with gender, age, histological type, smoking history, clinical stage and ECOG score in 135 patients. RRM1 and ERCC1 had significant positive correlation ( r = 0. 586, P<0.001). The effective rate, mean MST and TTP were 20. 0% , 10. 32 months, and (7. 50 ±4. 57)months in both positive group. In negative group which were superior to those in the both positive group were 71. 4% , 14. 55months and (10. 59 ±4.47) months. In either positive group, they were 58. 1% , 12. 87 months and (9. 40 ± 4. 08) months. There were statistical significance among the 3 groups at these aspects ( P < 0. 05). Conclusion Expressions of RRM1 and ERCC1 can predict the efficacy of the application of GP regimen on NSCLC.
展开▼
